Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein

Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein

Background The administration of recombinant interleukin 2 (IL-2) in oncology is frequently hampered by dose-limiting toxicities, including potentially lethal vascular leak syndrome. Antibody-IL-2 fusion proteins capable of preferential tumor localization have shown encouraging signs of activity in...

Full description

Saved in:
Bibliographic Details
Main Authors: Francesco Prisco, Dario Neri, Emanuele Puca, Eleonora Prodi, Cornelia Halin, Giulia Rotta, Ettore Gilardoni, Frauke Seehusen, Matilde Bocci, Claudia Comacchio, Sheila Dakhel Plaza
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/5/e010831.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/5/e010831.full

Similar Items